One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Finally, Wells Fargo & Company upgraded Blueprint Medicines from an "underweight" rating to an "equal weight" rating and set a $41.00 target price for the company in a report on Monday, January 2nd. Oppenheimer lowered Blueprint Medicines from an "outperform" rating to a "market perform" rating in a report on Wednesday, November 2nd. HC Wainwright reduced their target price on Blueprint Medicines from $80.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday, November 2nd. JMP Securities reduced their target price on Blueprint Medicines from $152.00 to $114.00 and set a "market outperform" rating for the company in a report on Friday, November 4th. Jefferies Financial Group reduced their price target on Blueprint Medicines from $84.00 to $80.00 in a report on Wednesday, November 2nd. Several other brokerages have also issued reports on BPMC. Needham & Company LLC's price objective suggests a potential upside of 43.44% from the company's current price. They currently have a $60.00 target price on the biotechnology company's stock.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |